Perelman School of Medicine at the University of Pennsylvania

Center for Research on Reproduction and Women's Health

Janos L. Tanyi

faculty photo
Assistant Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania
Attending Physician, Gynecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA
Department: Obstetrics and Gynecology

Contact information
University of Pennsylvania Health System,
Department of Obstetrics and Gynecology
Jordan Center for Gynecologic Cancer at Penn
Perelman Center for Advanced Medicine
3400 Civic Center Boulevard, 3 West
Philadelphia, PA 19104
Office: 215-662-3318
Fax: 215-349-5849
M.D. (Summa cum Laude)
University of Debrecen, Faculty of Medicine, Hungary , 1993.
Ph.D. (Summa cum Laude)
Semmelweis University, Faculty of Medicine, School of Clinical Sciences, Budapest, Hungary, 2008.
Post-Graduate Training
Residency Training, Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary, 1993-1998.
Postdoctoral Fellow and Research Scholar, University of Texas, MD Anderson Cancer Center, Houston, TX, 1999-2004.
Resident, Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas, 2004-2008.
Fellow, Gynecologic Oncology, Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA, 2008-2011.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

O'Hara MH, Stashwick C, Plesa G, Tanyi JL: Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers. Immunotherapy 9(9):767-80, Aug 2017.

Yang L, Zhang Y, Shan W, Hu Z, Yuan J, Pi J, Wang Y, Fan L, Tang Z, Li C, Hu X, Tanyi JL, Fan Y, Huang Q, Montone K, Dang CV, Zhang L: Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med 9(400), Jul 2017.

Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, June CH: Possible compartmental cytokine release syndrome in a patient with recurrent ovarian cancer after treatment with Mesothelin-targeted CAR-T cells. J Immunother 40(3):104-10, Apr 2017.

Randall L, Wenham RN, Dowdy SC, Low P, Tanyi JL: A Phase 2, Single-Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer. SGO 48th Annual Meeting on Women's Cancer. Scientific Plenary Session, Annual Meeting, National Harbor, MD, Mar 2017.

George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F: A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight 2(1):e89760, Jan 2017.

Tayni JL, Cory L, DeJesus E, Keating J, Predina J, Nie S, Desphande C, Low P, Singhal S: Intraoperative molecular imaging can identify sub-centimeter perioneal implants during ovarian cancer cytoreductive surgery. Eur J Gynaecol Oncol 38(4):589-95, Oct 2016.

Santoiemma PP, Reyes C, Wang LP, McLane MW, Feldman MD, Tanyi JL, Powell DJ Jr: Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer. Gynecol Oncol 143(1):120-7, Jul 2016.

Tanyi JL, Haas AR, Beatty GB, Stashwick CJ, O'Hara MH, Morgan MA, Porter DL, Melenhorst JJ, Plesa G, Lacey SF, June CH: Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer (suppl; abstr 5511). Oral presentation, Leveraging the Immuno-Molecular Landscape of Gynecologic Cancers ASCO Annual Meeting, Chicago, IL, J Clin Oncol 34 Jun 2016.

Haas RA, Plesa G, Torigian D, Moon E, O’Hara M, Beatty G, Tanyi JL, Nelson A, Kerr N, Lacey S, Melenhorst J, Albelda SA, June C: Phase I trial of lentiviral CART-meso cells in progressive malignant pleural mesothelioma (MPM). Poster, International Mesothelioma Interest Group Annual Meeting. Birmingham, UK, May 2016.

Jean S, Li J, Katsaros D, Wubbenhorst B, Maxwell KN, Fishbein L, McLane MW, Benedetto C, Canuto EM, Mitra N, Zhang L, Nathanson KL, Tanyi JL: Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations. Oncotarget 7(30):48577-585, May 2016.

back to top
Last updated: 01/16/2018
The Trustees of the University of Pennsylvania